In 2022, both the World Health Organisation (WHO) and International Consensus Classification (ICC) have updated the classification of acute myeloid leukaemia (AML) in order to reflect recent advances in disease understanding. In terms of secondary AML, there are now new definitions of therapy-related AML and AML with myelodysplasia-related changes. Furthermore, it is becoming more and more clear that also older patients benefit from intensive chemotherapy, followed by haematopoietic stem cell transplantation. With regard to Vyxeos Liposomal, a multitude of real-world studies could confirm the safety and efficacy that was observed in the randomised, phase III Study 301.